Liminal BioSciences completes plan of arrangement with Structured Alpha

Liminal BioSciences is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP, a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed on September 26. Pursuant to the Arrangement, SALP acquired all of the issued and outstanding common shares of Liminal BioSciences not currently owned by SALP or its affiliates and associates at a price of $8.50 per Share, payable in cash. As a result of the Arrangement, the Shares will no longer be listed on the Nasdaq Capital Market. In addition, the company will submit an application to cease to be a reporting issuer under applicable Canadian securities law, will file a certification and notice on Form 15 with the U.S. SEC to suspend its reporting obligations under U.S. securities laws and will otherwise terminate the company’s public reporting requirements.